Symbols

CSTL

Castle Biosciences·NASDAQ

--(--)

CSTL fundamentals

CSTL Q4 2025 Earnings

Castle Biosciences (CSTL) released its earnings on Feb 26, 2026: revenue was 87.01M (YoY +1.39%), beat estimates; EPS was -0.08 (YoY -125.00%), beat estimates.

Revenue / YoY

87.01M

+1.39%

EPS / YoY

-0.08

-125.00%

Report date

Feb 26, 2026

CSTL Earnings Call Summary for Q4,2025

Revenue Growth: 2025 total $344.2M, driven by 9% DecisionDx-Melanoma and 86% TissueCypher growth.
New Product Momentum: AdvanceAD-Tx hits 500+ orders in 5 weeks, targeting 2027-2028 material revenue.
Pipeline Expansion: GI device (Q2 2026 enrollment) and EIS technology (Q2 2026 study) for Barrett's and atopic dermatitis.
Financial Outlook: 2026 guidance $340-350M, 69.2% gross margin, $299.5M cash.
Strategic Moves: FDA 510(k) for biomarker law compliance, 90/10% rep focus on AD, potential SCC reactivation.

Earnings

EPS

Revenue

Revenue & Expenses

CSTL has released its 2025 Q4 earnings report, with revenue of 87.01M, reflecting a YoY change of 0.81%, and net profit of -2.33M, showing a YoY change of -124.32%. The Sankey diagram below clearly presents CSTL's revenue sources and cost distribution.

Key Indicators

Castle Biosciences (CSTL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Castle Biosciences (CSTL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Castle Biosciences (CSTL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Castle Biosciences (CSTL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown